AUTHOR=Devi-Marulkar Priyanka , Moraes-Cabe Carolina , Campagne Pascal , Corre Béatrice , Meghraoui-Kheddar Aida , Bondet Vincent , Llibre Alba , Duffy Darragh , Maillart Elisabeth , Papeix Caroline , Pellegrini Sandra , Michel Frédérique 

TITLE=Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment

JOURNAL=Frontiers in Immunology

VOLUME=Volume 12 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.628375

DOI=10.3389/fimmu.2021.628375

ISSN=1664-3224

ABSTRACT=<sec><title>Background</title><p>Interferon beta (IFN<italic>β</italic>) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades. However, there is still a lack of treatment response markers that correlate with the clinical outcome of patients.</p></sec><sec><title>Aim</title><p>To determine a combination of cellular and molecular blood signatures associated with the efficacy of IFN<italic>β</italic> treatment using an integrated approach.</p></sec><sec><title>Methods</title><p>The immune status of 40 RRMS patients, 15 of whom were untreated and 25 that received IFN<italic>β</italic>1a treatment (15 responders, 10 non-responders), was investigated by phenotyping regulatory CD4<sup>+</sup> T cells and naïve/memory T cell subsets, by measurement of circulating IFN<italic>α</italic>/<italic>β</italic> proteins with digital ELISA (Simoa) and analysis of ~600 immune related genes including 159 interferon-stimulated genes (ISGs) with the Nanostring technology. The potential impact of HLA class II gene variation in treatment responsiveness was investigated by genotyping <italic>HLA</italic>-<italic>DRB1, -DRB3,4,5, -DQA1</italic>, and -<italic>DQB1</italic>, using as a control population the <italic>Milieu Interieur</italic> cohort of 1,000 French healthy donors.</p></sec><sec><title>Results</title><p>Clinical responders and non-responders displayed similar plasma levels of IFN<italic>β</italic> and similar ISG profiles. However, non-responders mainly differed from other subject groups with reduced circulating naïve regulatory T cells, enhanced terminally differentiated effector memory CD4<sup>+</sup> T<sub>EMRA</sub> cells, and altered expression of at least six genes with immunoregulatory function. Moreover, non-responders were enriched for <italic>HLA-DQB1</italic> genotypes encoding DQ8 and DQ2 serotypes. Interestingly, these two serotypes are associated with type 1 diabetes and celiac disease. Overall, the immune signatures of non-responders suggest an active disease that is resistant to therapeutic IFN<italic>β</italic>, and in which CD4<sup>+</sup> T cells, likely restricted by DQ8 and/or DQ2, exert enhanced autoreactive and bystander inflammatory activities.</p></sec>